Ongoing Clinical Trials for Metastatic Liposarcoma
There are currently 3 ongoing clinical trials investigating new treatment options for metastatic liposarcoma. These studies are testing various combinations of targeted therapies and immunotherapies in patients whose cancer has spread to other parts of the body. Trials are being conducted across several European countries, including Denmark, Sweden, Norway, Germany, Slovakia, and Czechia.
Clinical trial locations
- Czechia
- Denmark
- Germany
- Norway
- Slovakia
- Sweden
Study of Pemigatinib and Retifanlimab for Patients with Advanced Dedifferentiated Liposarcoma
This trial is testing a combination of two medications for patients with dedifferentiated liposarcoma, a rare and aggressive form of cancer that develops in fat cells. The study is examining whether pemigatinib, taken as a tablet, combined with retifanlimab, given through an intravenous infusion, can help control this type of cancer.
Main inclusion criteria: To participate in this study, patients must be at least 18 years old and have a confirmed diagnosis of dedifferentiated liposarcoma with positive results for MDM2 tests. Patients need to have at least one tumor that can be measured using CT scans and cannot be removed by surgery. Participants must be willing to provide tumor tissue samples through a biopsy at certain times during the study, though previous samples may be used if available. Patients should be able to perform daily activities reasonably well, with a performance status of 0-2 on the ECOG scale.
Main exclusion criteria: Patients with cancer types other than dedifferentiated liposarcoma cannot participate. Those who are pregnant or breastfeeding, have recently participated in another clinical trial, or have serious health conditions that might interfere with the study are also excluded. Patients who are allergic to the study medications or cannot provide informed consent are not eligible.
Study focus: The trial evaluates how long patients live without their disease getting worse, looking specifically at progression-free survival at 24 weeks. The study also tracks overall survival, response to treatment, side effects, and changes in quality of life. Regular monitoring includes assessments of tumor response, laboratory tests, and physical examinations throughout the treatment period, which is expected to conclude by April 2027.
Investigational drugs: Pemigatinib works by targeting specific pathways in cancer cells that control their growth and survival, potentially slowing disease progression. Retifanlimab helps the immune system recognize and attack cancer cells by blocking a protein called PD-1, improving the body’s natural ability to fight cancer.
Study of Trabectedin alone versus Trabectedin with tTF-NGR combination therapy in adults with metastatic or refractory soft tissue sarcoma who failed first-line treatment
This trial compares two treatment approaches for patients with soft tissue sarcoma, including liposarcoma, whose cancer has spread or did not respond to previous treatment. The study tests whether adding an experimental drug called tTF-NGR to standard trabectedin chemotherapy can help control the cancer longer than trabectedin alone.
Main inclusion criteria: Patients must be between 18 and 75 years old and have advanced or metastatic soft-tissue sarcoma that either did not respond to previous anthracycline treatment or where anthracyclines cannot be used. They must have confirmed high-grade soft tissue sarcoma of specific types, including several types of liposarcoma. The tumor must test positive for a protein marker called CD13, and patients need at least one measurable tumor that has not been treated with radiation. Participants must have a life expectancy of at least 3 months and an ECOG performance status of 2 or less. Women of childbearing potential must have a negative pregnancy test and agree to use effective birth control during and after the study.
Main exclusion criteria: Those outside the age range of 18-75 years cannot participate. Patients without confirmed soft-tissue sarcoma, those who test negative for CD13, or those currently pregnant or breastfeeding are excluded. People with severe heart, liver, or kidney problems, active uncontrolled infections, or other active cancers requiring treatment are not eligible. Previous treatment with trabectedin or known allergies to study medications also exclude patients from participation.
Study focus: The trial aims to determine if combining trabectedin with tTF-NGR keeps cancer under control longer than trabectedin alone. Patients receive treatment for up to 360 days through intravenous infusion. Regular medical examinations and imaging tests monitor how the cancer responds to treatment. The study specifically focuses on tumors with CD13 positivity, which is determined through laboratory testing.
Investigational drugs: Trabectedin is a cancer medication that interferes with cancer cell growth and division, typically used when other treatments have not worked. tTF-NGR is an experimental drug designed to help concentrate the chemotherapy medication inside the tumor by targeting blood vessels in tumors, potentially making the cancer treatment more effective.
Study on PF-07220060, Letrozole, and Fulvestrant for Patients with Advanced Breast Cancer, Prostate Cancer, and Other Solid Tumors
This clinical trial studies advanced solid tumors, including liposarcoma, that have spread beyond their original location. The main treatment being tested is a new medication called PF-07220060, which is evaluated both alone and combined with other cancer treatments.
Main inclusion criteria: Participants must be at least 18 years old and have a type of cancer that fits the study requirements, including liposarcoma or other tumors with specific genetic changes called CDK4 or CCND1 amplification. Patients must have tried existing treatments that are no longer effective or cannot be tolerated. They need adequate liver, bone marrow, and kidney function based on specific blood test results. Participants must be willing to sign a consent form, attend scheduled visits, follow the treatment plan, and undergo necessary tests. They must have an ECOG performance status of 0 or 1, meaning they can be fully active or have some restrictions but can still do light work.
Main exclusion criteria: Patients with cancer types not specified in the study cannot participate. Those without tumors showing CDK4 or CCND1 amplification are excluded. Patients outside the specified age range or not part of the designated clinical trial groups are not eligible.
Study focus: The trial assesses the safety and effectiveness of PF-07220060 in treating advanced cancers. Participants receive the medication in tablet form, and in some cases, it is combined with other cancer treatments. The study explores how the body processes the medication and how it affects tumors. Some participants receive a placebo to help compare treatment effects. The trial consists of different parts, each focusing on specific cancer types and treatment combinations. Regular monitoring tracks safety and side effects, helping determine the best dose for future research. The trial is expected to continue until July 2026.
Investigational drugs: PF-07220060 is an experimental medication targeting specific proteins involved in cell cycle regulation, potentially inhibiting tumor growth. In some cases, it is combined with letrozole or fulvestrant for breast cancer treatment, which work by lowering estrogen levels or blocking estrogen effects to slow cancer growth.
Summary
Three clinical trials are currently recruiting patients with metastatic liposarcoma across several European countries. These studies represent different therapeutic approaches, including targeted therapies that block specific cancer growth pathways, immunotherapies that enhance the body’s immune response, and chemotherapy combinations designed to concentrate treatment directly within tumors.
The trials are geographically distributed across Scandinavia, Central Europe, and Eastern Europe, with Denmark, Sweden, and Norway hosting the dedifferentiated liposarcoma study, Germany conducting the soft tissue sarcoma trial, and Slovakia and Czechia participating in the broader solid tumor study. All three trials require patients to have advanced or metastatic disease that has either progressed despite previous treatment or is not amenable to surgery.
A common theme across these studies is the investigation of combination therapies rather than single-agent approaches, suggesting a trend toward multi-targeted treatment strategies. Two of the trials specifically require biomarker testing—MDM2 for dedifferentiated liposarcoma and CD13 for soft tissue sarcoma—reflecting the move toward personalized medicine based on tumor characteristics. Patients interested in participating should discuss eligibility criteria with their healthcare team, as each trial has specific requirements regarding previous treatments, performance status, and organ function.
